And then

routinely testing for DLL3 expression on newly diagnosed small cell patients.

I would say we do not at our institution.

It was a requirement of the clinical trial that patients were tested and were overexpressing.

But I believe that Dr. Cooper reported in her didactic portion about 85% of small cell patients will express DLL3.

So we don't wait for that given the urgency usually to start therapy on this population.

Like she, I mean, it can really make a big difference for these people.

And then a question came up about using prophylactic.

And can you talk a little bit about why, when, why, you know, Danone decided to get into the plant-based product development business, um, and how it's changed since then?

Yeah, sure.

Happy to.

Um, well, first of all, uh, Silk is, um, a brand that's been around for a very long time.

It really was the pioneer in plant-based beverages, first with soy milk.

Um, Danone saw that consumers were increasingly consuming more plant-based food and beverages in their diets, a consumer in particular we like to call flexitarians, um, embracing both dairy and plant-based alternatives, uh, for either lifestyle or health reasons, um, and wanted to enter into the plant-based market, and so, uh, purchased, um, the Silk brand as part of a collection of brands, um, by purchasing a company called WhiteWave in, uh, 2017.

Um, and really, uh, since we've made that acquisition, um, have tried to marry what was kind of a legacy, as you mentioned, uh, you know, over 100-plus years, um, uh, experience in nutrition and, um, science and bringing, you know, uh, really nutritious products to the, to the masses with a legacy, um, in plant-based food and bev in the, in the brands that we purchased from WhiteWave.

Are there any recent, uh, new plant-based products, foods, or beverages that, uh, you think are delivering to those needs for today's consumers?